PT-141
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and melanocortin receptor agonist (primarily MC3R/MC4R).
- Vial Size
- 10mg
- Molecular Weight
- 1025.18 g/mol
- Half-life
- ~2 hours
- Latest Lot Purity
- 99.32%
Mechanism of Action
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and melanocortin receptor agonist (primarily MC3R/MC4R). Studied for its central-nervous-system mediated effects on arousal and behavior in research models.
Research Context
- Melanocortin receptor pharmacology
- CNS-mediated arousal research models
- Behavioral pharmacology studies
Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH
Lot NX-046 · Verified at 99.32%
Plasma Profile & Protocol
Modelled plasma concentration over time, reconstitution calculator, and a literature-derived research protocol for PT-141.
Illustrative Bateman model derived from published half-life and absorption data. For research-context visualisation only.
Solve for syringe units assuming a U-100 insulin syringe. Defaults seeded from the PT-141 monograph.
U-100 insulin syringe assumed (100 units = 1 mL). For research dosing visualisation only. Verify all dilutions independently.
- Typical Dose
- 1–2 mg
- Frequency
- As-needed, ≤2× weekly
- Cycle Length
- Per protocol
- Route
- Subcutaneous
For Research Use Only · This monograph summarises publicly available research literature for educational, in-vitro and laboratory research purposes only. Nexora Labs products are not drugs, food, supplements, or cosmetics, and are not intended to diagnose, treat, cure or prevent any condition.